{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:08:13Z","timestamp":1778800093380,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.seizure.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:39:49Z","timestamp":1775666389000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives"],"prefix":"10.1016","volume":"138","author":[{"given":"Giovanni Battista","family":"Dell\u2019Isola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Roberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Salpietro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2026.04.003_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.674483","article-title":"The pharmacoresistant epilepsy: an overview on existent and new emerging therapies","volume":"12","author":"Fattorusso","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0002","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2174\/1570159X20666220706102708","article-title":"Epilepsy and cognitive impairment in childhood and adolescence: A mini-review","volume":"21","author":"Operto","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.832929","article-title":"Improving therapy of pharmacoresistant epilepsies: the role of fenfluramine","volume":"13","author":"Dini","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17425255.2024.2329733","article-title":"Cannabidiol: metabolism and clinical efficacy in epileptic patients","volume":"20","author":"Dell'Isola","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14656566.2024.2373350","article-title":"Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies","volume":"25","author":"Dell'Isola","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2026.04.003_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0960-0760(90)90490-C","article-title":"Neurosteroids: a new brain function?","volume":"37","author":"Baulieu","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135849","article-title":"Sex neurosteroids: hormones made by the brain for the brain","volume":"753","author":"Fester","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.seizure.2026.04.003_bib0008","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pharmthera.2018.06.011","article-title":"Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases","volume":"191","author":"Schverer","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.seizure.2026.04.003_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.572511","article-title":"Rapid estrogenic and androgenic neurosteroids effects in the induction of long-term synaptic changes: implication for early memory formation","volume":"14","author":"Tozzi","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABA(A) receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0011","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1038\/s41467-023-40800-1","article-title":"Structural insights into opposing actions of neurosteroids on GABAA receptors","volume":"14","author":"Legesse","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.seizure.2026.04.003_bib0012","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.steroids.2011.09.002","article-title":"Neurosteroid modulation of N-methyl-D-aspartate receptors: molecular mechanism and behavioral effects","volume":"76","author":"Korinek","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.seizure.2026.04.003_bib0013","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1476-5381.2011.01816.x","article-title":"Access of inhibitory neurosteroids to the NMDA receptor","volume":"166","author":"Borovska","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainres.2018.02.031","article-title":"Neurosteroid regulation of GABAA receptors: A role in catamenial epilepsy","volume":"1703","author":"Joshi","year":"2019","journal-title":"Brain Res"},{"key":"10.1016\/j.seizure.2026.04.003_bib0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WCO.0b013e32833735cf","article-title":"Neurosteroids and epilepsy","volume":"23","author":"Biagini","year":"2010","journal-title":"Curr Opin Neurol"},{"issue":"24","key":"10.1016\/j.seizure.2026.04.003_bib0016","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.3390\/ijms21249391","article-title":"Neurosteroids and focal epileptic disorders","volume":"21","author":"L\u00e9vesque","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0017","series-title":"Jasper's Basic Mechanisms of the Epilepsies [Internet]","article-title":"Neurosteroids \u2014 Endogenous regulators of seizure susceptibility and role in the treatment of epilepsy","author":"Reddy","year":"2012"},{"key":"10.1016\/j.seizure.2026.04.003_bib0018","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000509093","article-title":"Allopregnanolone and pregnanolone are reduced in the hippocampus of epileptic rats, but only Allopregnanolone correlates with seizure frequency","volume":"111","author":"Lucchi","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.seizure.2026.04.003_bib0019","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/molpharm.121.000385","article-title":"The sulfated steroids pregnenolone sulfate and dehydroepiandrosterone sulfate inhibit the \u03b11\u03b23\u03b32L GABAA receptor by stabilizing a novel nonconducting State","volume":"101","author":"Pierce","year":"2022","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1159\/000531148","article-title":"Sex hormones, neurosteroids, and glutamatergic neurotransmission: A review of the literature","volume":"113","author":"Goyette","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.seizure.2026.04.003_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.eplepsyres.2013.06.008","article-title":"Dehydroepiandrosterone's antiepileptic action in FeCl3-induced epileptogenesis involves upregulation of glutamate transporters","volume":"106","author":"Mishra","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.04.003_bib0022","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0023","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41583-024-00805-1","article-title":"mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment","volume":"25","author":"Ravizza","year":"2024","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2019.100788","article-title":"Neurosteroids as regulators of neuroinflammation","volume":"55","author":"Yilmaz","year":"2019","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.108525","article-title":"Progesterone receptor-mediated actions and the treatment of central nervous system disorders: an up-date of the known and the challenge of the unknown","volume":"153","author":"Gonz\u00e1lez","year":"2020","journal-title":"Steroids"},{"key":"10.1016\/j.seizure.2026.04.003_bib0026","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0027","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10571-020-00851-0","article-title":"Response of voltage-gated sodium and calcium channels subtypes on dehydroepiandrosterone treatment in iron-induced epilepsy","volume":"4","author":"Prakash","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s004240050745","article-title":"Modulation of cloned human neuronal voltage-gated potassium channels (hKv1.1 and hKv2.1) by neurosteroids","volume":"437","author":"Wang","year":"1998","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.seizure.2026.04.003_bib0029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14656566.2024.2342413","article-title":"A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy","volume":"25","author":"Khan","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2026.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1111\/j.1528-1167.2007.01182.x","article-title":"Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy","volume":"48","author":"Pieribone","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.17826","article-title":"Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: two-year open-label extension follow-up","volume":"65","author":"Olson","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.13705","article-title":"Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures","volume":"58","author":"Sperling","year":"2017","journal-title":"Epilepsia"},{"issue":"P5.237","key":"10.1016\/j.seizure.2026.04.003_bib0034","article-title":"Double-blind, randomized, placebo-controlled phase 3 trial to determine the efficacy and safety of Ganaxolone as adjunctive therapy for adults with drug-resistant focal-onset seizures (P5.237)","volume":"88","author":"Lappalainen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.04.003_bib0035","unstructured":"Marinus Pharmaceuticals (sponsor). Randomized Therapy In Status Epilepticus (RAISE). (ClinicalTrials.gov Identifer: NCT04391569) (last update posted on 2025-05-29) Available from: https:\/\/clinicaltrials.gov\/study\/NCT04391569 (access date 03\/04\/2026)."},{"key":"10.1016\/j.seizure.2026.04.003_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ph11010017","article-title":"Interactions between epilepsy and plasticity","volume":"11","author":"Jarero-Basulto","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.seizure.2026.04.003_bib0037","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.3390\/ijms22115991","article-title":"An unbalanced synaptic transmission: cause or consequence of the amyloid oligomers neurotoxicity?","volume":"22","author":"Sciaccaluga","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0038","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/ijms25031377","article-title":"Locally synthetized 17-\u03b2-estradiol reverses amyloid-\u03b2-42-induced hippocampal long-term potentiation deficits","volume":"25","author":"Bellingacci","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0039","first-page":"1698","article-title":"Brain-derived estrogen and neurological disorders","volume":"11","author":"Brann","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.seizure.2026.04.003_bib0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.123.001817","article-title":"Protective activity of novel hydrophilic synthetic neurosteroids on organophosphate status epilepticus-induced chronic epileptic seizures, non-convulsive discharges, high-frequency oscillations, and electrographic ictal biomarkers","volume":"388","author":"Ramakrishnan","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2026.04.003_bib0041","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.117.246660","article-title":"3\u03b2-Methyl-neurosteroid analogs are preferential positive allosteric modulators and direct activators of extrasynaptic \u03b4-subunit \u03b3-aminobutyric acid type A receptors in the Hippocampus Dentate Gyrus subfield","volume":"365","author":"Chuang","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2026.04.003_bib0042","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1111\/bcp.15225","article-title":"Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers","volume":"88","author":"Wang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0043","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","article-title":"The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors","volume":"33","author":"Paul","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0044","doi-asserted-by":"crossref","first-page":"34388","DOI":"10.1074\/jbc.M403938200","article-title":"Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function","volume":"279","author":"Butchbach","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.seizure.2026.04.003_bib0045","series-title":"American Epilepsy Society Annual Meeting","article-title":"Proposed mechanism of action of soticlestat as an antiseizure medication","author":"Murthy","year":"2023"},{"key":"10.1016\/j.seizure.2026.04.003_bib0046","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1111\/epi.18056","article-title":"Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development","volume":"65","author":"Bialer","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106027","article-title":"Neuroinflammation microenvironment sharpens seizure circuit","volume":"178","author":"Villasana-Salazar","year":"2023","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.seizure.2026.04.003_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105835","article-title":"Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy","volume":"173","author":"Salamone","year":"2022","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.seizure.2026.04.003_bib0049","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/cts.13517","article-title":"Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults","volume":"16","author":"Yin","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.seizure.2026.04.003_bib0050","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1111\/epi.17376","article-title":"Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development","volume":"63","author":"Bialer","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0051","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1111\/bcp.14854","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects","volume":"87","author":"Wang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0052","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.15917","article-title":"Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers","volume":"90","author":"Yin","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0053","series-title":"American Epilepsy Society Annual Meeting","article-title":"Soticlestat in vitro metabolism and drug\u2013drug interactions: comprehensive investigations display minimal notable interactions","author":"Ballard","year":"2023"},{"issue":"4","key":"10.1016\/j.seizure.2026.04.003_bib0054","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/epd2.20069","article-title":"Pharmacological aspects of antiseizure medications: from basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring","volume":"25","author":"Johannessen Landmark","year":"2023","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2026.04.003_bib0055","series-title":"American Epilepsy Society Annual Meeting","article-title":"Physiologically based pharmacokinetic modeling to predict drug\u2013drug interactions of soticlestat","author":"Yin","year":"2023"},{"key":"10.1016\/j.seizure.2026.04.003_bib0056","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/dmd.123.001444","article-title":"Effects of strong inhibition of CYP3A and UGT1A9 and strong induction of CYP3A on the pharmacokinetics, safety, and tolerability of Soticlestat: two drug-drug interaction studies in healthy volunteers","volume":"52","author":"Yin","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.seizure.2026.04.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.04.003_bib0058","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/epi.17367","article-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","volume":"63","author":"Hahn","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0059","unstructured":"Takeda (sponsor). A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1). (ClinicalTrials.gov Identifer: NCT03635073) (last update posted on 2024-02-21) Available from: https:\/\/clinicaltrials.gov\/study\/NCT03635073 (access date 06\/09\/2024)."},{"issue":"17_supplement_2","key":"10.1016\/j.seizure.2026.04.003_bib0060","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1212\/WNL.0000000000202980","article-title":"Long-term treatment effects of soticlestat in patients with Dravet syndrome or Lennox\u2013Gastaut Syndrome: Interim data from the ENDYMION 1 trial (S44.004)","volume":"100","author":"Yao","year":"2023","journal-title":"Neurology [Internet]"},{"key":"10.1016\/j.seizure.2026.04.003_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109173","article-title":"Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)","volume":"142","author":"Demarest","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.04.003_bib0062","unstructured":"Takeda (sponsor). A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome. (ClinicalTrials.gov Identifer: NCT04938427) (last update posted on 2024-08-21) Available from: https:\/\/clinicaltrials.gov\/study\/NCT04938427 (access date 06\/09\/2024)."},{"key":"10.1016\/j.seizure.2026.04.003_bib0063","doi-asserted-by":"crossref","DOI":"10.1002\/epi.70164","article-title":"Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome","author":"Sullivan","year":"2026","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/epi.70216","article-title":"A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome","author":"Guerrini","year":"2026","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0065","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/epi.17737","article-title":"Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial","volume":"64","author":"Sullivan","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.003_bib0066","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut Syndrome: A randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2026.04.003_bib0067","doi-asserted-by":"crossref","first-page":"e1213","DOI":"10.1002\/prp2.1213","article-title":"Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function","volume":"12","author":"Yin","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.seizure.2026.04.003_bib0068","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/dmd.123.001444","article-title":"Effects of strong inhibition of cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and strong induction of cytochrome P450 3A on the pharmacokinetics, safety, and tolerability of Soticlestat: two drug-drug interaction studies in healthy volunteers","volume":"52","author":"Yin","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.seizure.2026.04.003_bib0069","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neures.2024.06.005","article-title":"Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models","volume":"208","author":"Hasegawa","year":"2024","journal-title":"Neurosci Res"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:21:33Z","timestamp":1778797293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126000944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":69,"alternative-id":["S1059131126000944"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.04.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}